Literature DB >> 19746360

Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.

Sarah Keppner1, Ewgenij Proschak, Gisbert Schneider, Birgit Spänkuch.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19746360     DOI： 10.1002/cmdc.200900338

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  13 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

Review 2.  Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.

Authors:  Ravichandran N Murugan; Jung-Eun Park; Eun-Hee Kim; Song Yub Shin; Chaejoon Cheong; Kyung S Lee; Jeong Kyu Bang
Journal:  Mol Cells       Date:  2011-07-29       Impact factor: 5.034

3.  Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.

Authors:  Franz Rödel; Sarah Keppner; Gianni Capalbo; Robina Bashary; Manfred Kaufmann; Claus Rödel; Klaus Strebhardt; Birgit Spänkuch
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

4.  Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.

Authors:  Indranil Basu; Joseph Locker; Maria B Cassera; Thomas J Belbin; Emilio F Merino; Xinyuan Dong; Ivan Hemeon; Gary B Evans; Chandan Guha; Vern L Schramm
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

5.  A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors.

Authors:  Kohei Tsuji; David Hymel; Terrence R Burke
Journal:  Anal Methods       Date:  2020-09-03       Impact factor: 2.896

6.  Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors.

Authors:  Shuai Lu; Hai-Chun Liu; Ya-Dong Chen; Hao-Liang Yuan; Shan-Liang Sun; Yi-Ping Gao; Pei Yang; Liang Zhang; Tao Lu
Journal:  Int J Mol Sci       Date:  2011-12-01       Impact factor: 5.923

7.  Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.

Authors:  Lisa Lange; Peter Hemmerich; Birgit Spänkuch
Journal:  Oncotarget       Date:  2015-09-22

Review 8.  Molecular dynamics of PLK1 during mitosis.

Authors:  Stephane Schmucker; Izabela Sumara
Journal:  Mol Cell Oncol       Date:  2014-10-29

Review 9.  PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.

Authors:  Shiv Kumar; Jaebong Kim
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

10.  Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status.

Authors:  Lisa Lange; Sarah Keppner-Witter; Juline Grigat; Birgit Spänkuch
Journal:  Oncotarget       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.